Feedback / Questions
Imfinzi (durvalumab) - AstraZeneca
paclitaxel - Atlanthera
Keytruda (pembrolizumab) - Merck (MSD)
https://www.oncnursingnews.com/view/new-research-seeks-to-incorporate-immunotherapy-into-early-lines-of-escc-treatment
Mar 12, 2022
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Prev
Next